Auspex Pharmaceuticals Receives FDA Orphan Drug Designation

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Auspex Pharmaceuticals Receives FDA Orphan Drug Designation of SD-809 for Treatment of Huntington's Disease

LA JOLLA, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX ), a biopharmaceutical company dedicated to developing innovative medicines for people with movement disorders and other rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation of Auspex's investigational compound SD-809 for treatment of Huntington's disease. Auspex is currently evaluating the efficacy and safety of SD-809 for treating chorea associated with this disorder in a Phase 3 registration clinical trial and is on track to announce topline data from this study in December 2014.

"The orphan drug designation of SD-809 marks a major regulatory milestone for Auspex and a significant step forward in our goal to bring this novel treatment approach to patients as quickly as possible," said Pratik Shah, president and CEO of Auspex. "Huntington's disease is a rare and devastating genetic disorder with very limited treatment options. The orphan drug designation recognizes the significant need that exists among individuals living with this disease."

The FDA's Orphan Drug program offers orphan status to drugs and biologics that are intended for the treatment of rare diseases affecting fewer than 200,000 people in the U.S. The designation provides sponsors with development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design and an exemption from FDA user fees.

About Auspex Pharmaceuticals

Auspex Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines for hyperkinetic movement disorders and other rare diseases. Auspex employs its proprietary technology to create patent-protected, new chemical entities from known, clinically proven pharmacologics. The company's lead product SD-809 is in final stages of development for the treatment of chorea associated with Huntington's disease, a neurodegenerative movement disorder that impacts cognition, behavior and movements. In addition, Auspex is investing in the broad potential of SD-809 for the treatment of other movement disorders, including tardive dyskinesia and tics associated with Tourette syndrome. The company's pipeline also includes SD-560, being developed for fibrotic conditions. For further information, please visit the company's website www.auspexpharma.com .

Forward-Looking Statements

Statements made in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Auspex's ability to successfully complete its ongoing clinical trials and development programs and Auspex's ability to obtain regulatory approval for its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: Auspex's future preclinical studies and clinical trials may not be successful; changes in regulatory requirements in the United States and foreign countries may prevent or significantly delay regulatory approval of Auspex's product candidates; Auspex may change its plans to develop and commercialize its product candidates; the U.S. Food and Drug Administration (FDA) may not agree with Auspex's interpretation of the data from clinical trials of its product candidates; Auspex may decide, or the FDA may require Auspex, to conduct additional clinical trials or to modify Auspex's ongoing clinical trials; Auspex may experience delays in the commencement, enrollment, completion or analysis of clinical testing for its product candidates, or significant issues regarding the adequacy of its clinical trial designs or the execution of its clinical trials, which could result in increased costs and delays, or limit Auspex's ability to obtain regulatory approval; the third parties with whom Auspex has partnered with for the development of its product candidates and upon whom Auspex relies to conduct its clinical trials and manufacture its product candidates may not perform as expected; Auspex's product candidates may not receive regulatory approval or be successfully commercialized; unexpected adverse side effects or inadequate therapeutic efficacy of Auspex's product candidates could delay or prevent regulatory approval or commercialization; Auspex may be unable to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; Auspex's ability to obtain additional financing; and the accuracy of Auspex's estimates regarding expenses, future revenues and capital requirements. All forward-looking statements contained in this press release speak only as of the date on which they were made. Other risks and uncertainties affecting Auspex are described more fully in Auspex's filings with the Securities and Exchange Commission. Auspex undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

For Media: Dan Budwick at Pure Communications, Inc. (973) 271-6085 For Investors: Monique Allaire Lyons (781) 631-0759

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Luxury's €1.5 Trillion Market Has Moved to Memories

Updated Category News Views 93

A €1.5 trillion market that cannot grow much is still a market worth fighting over, but luxury's old playbook is looking awfully tired. Bain's 2026 view is for global luxury spending to land somewhere between flat and up 2% at constant exchange rates versus 2025. That is stability, not a victory parade. Yet the total market remains 16% to 22% above 2019 levels, and the...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 141

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Envision and Tai Tam Put 45 MW Wind Bet to Work in Vietnam

Updated Category News Views 116

A wind site averaging 6.5 meters per second can look unremarkable on a map, yet that is precisely where equipment choices start separating serious developers from brochure merchants. Envision Energy and Vietnam's Tai Tam Group are taking that test on with the 45 MW Phuoc Dan wind project in Khanh Hoa Province. The arrangement follows five years of cooperation, but the...

Continue Reading
Cadence Marks $2.7 Million for St. Jude Family Care

Updated Category News Views 21

Small Wheels, Serious Purpose Tiny tricycles, flour-dusted bake-sale tables, and family pledges have pushed Cadence Education’s St. Jude partnership to $2.7 million since 2018. That number is not a flashy balance-sheet item, nor should anybody try to dress it up as one. It is the accumulated result of school communities showing up year after year, and in a sector built...

Continue Reading
Unishippers Climbs 18 Slots on 32.4% Sales Growth Run

Updated Category News Views 184

Thirty new franchise units can move the needle fast Unishippers did not inch its way up the Franchise Times Top 400; it put up a number that deserves a hard look. Sales rose 32.4% in 2025, the company added 30 franchise units, and the result was an 18-place jump to No. 81 on the 2026 ranking. In the shipping category, it was named the sales-growth leader. For a business...

Continue Reading
TGHL Eyes U.S. Battery Shift Through EnChem Merger

Updated Category News Views 112

A Policy Squeeze Is Rewriting the Battery Map Battery supply chains are getting shoved through a narrower gate, and that is exactly why this proposed deal deserves a hard look. The GrowHub Limited wants to acquire EnChem America, a Georgia-based lithium-ion battery electrolyte producer, and the timing is plainly built around Washington's push to reduce reliance on...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 107

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 165

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 75

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
Halff Elevates People and Delivery Leadership Team

Updated Category News Views 90

Infrastructure outfits rarely make much noise when they reshuffle leadership, but Halff’s Nov. 18 announcement deserves a closer look than the usual executive-title confetti. The employee-owned consulting firm has put Greg Carpenter in the chief people officer seat and named Leigh Hollis chief delivery officer. One role is aimed squarely at the human machinery; the...

Continue Reading

Top 5 Most Recently Viewed Articles

Venus Concept Strengthens Financial Position with Debt Exchange

Updated Category News Views 173

Venus Concept Optimizes Capital Structure through Debt Exchange Venus Concept Inc. is making waves in the medical aesthetic technology industry with its recent strategic financial decision. The company, known for its innovative solutions, has successfully exchanged $11 million worth of subordinated convertible notes for 379,311 shares of Series Y preferred stock. This...

Continue Reading
Understanding the Recent Decline of Gentex Corporation Stock

Updated Category News Views 284

Why Is Gentex Corporation Stock Down? Gentex Corporation (NASDAQ:GNTX) shares have recently faced a decline after revealing third-quarter earnings that fell short of expectations. The drop can be largely attributed to lower-than-expected earnings per share (EPS) and sales figures. Quarterly Earnings Performance For the third quarter, Gentex reported adjusted earnings of...

Continue Reading
Elliott Pressures Northern Star: Board Shake-Up Needed

Updated Category News Views 59

Reckoning Time for Northern Star Resources Well, it's about time someone rattled the cage at Northern Star. Elliott Management, never one to sit on its laurels, is clapping back at the board with a stern letter, raising eyebrows and hopes for a shake-up. They're putting their 5.6% stake to work, backing their talk with a lineup of heavyweight board candidates. The message...

Continue Reading
CBD's Role in Supporting World Cup Soccer Players

Updated Category News Views 60

World Cup Sparks Focus on Player Recovery An event like the FIFA World Cup doesn't just put its spotlight on dazzling goals and nail-biting penalty shootouts; it throws the grueling demands placed on players into sharp relief. With fixtures spread across sprawling global schedules, these athletes barely get time to breathe between matches. Rest Rules Let Players Recharge...

Continue Reading
Middlefield Canadian Income PCC: Major Holdings Announcement

Updated Category News Views 185

Overview of Middlefield Canadian Income PCC Holdings Middlefield Canadian Income PCC is actively engaged in managing major holdings and ensuring transparency in its share structure. The company recently issued a comprehensive notification, detailing the current shareholding status and changes in voting rights, importantly reflecting the interests of its shareholders....

Continue Reading